Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators

Deferoxamine (DFO) is an FDA‐approved iron‐chelating agent which shows good therapeutic efficacy, however, its short blood half‐life presents challenges such as the need for repeated injections or continuous infusions. Considering the lifelong need of chelating agents for iron overload patients, a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Seung Hun, Kim, Richard S., Stiles, Wesley R., Jo, Minjoo, Zeng, Lingxue, Rho, Sunghoon, Baek, Yoonji, Kim, Jonghan, Kim, Moon Suk, Kang, Homan, Choi, Hak Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130884/
https://www.ncbi.nlm.nih.gov/pubmed/35343104
http://dx.doi.org/10.1002/advs.202200872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130884/
https://www.ncbi.nlm.nih.gov/pubmed/35343104
http://dx.doi.org/10.1002/advs.202200872

Ejemplares similares